Definium Therapeutics, Inc., formerly known as Mind Medicine (MindMed) Inc., is a clinical-stage biopharmaceutical company headquartered in New York. The company is dedicated to developing a new generation of treatments for brain health disorders by leveraging the therapeutic potential of psychedelic and psychoplastogenic drugs. As a pre-revenue clinical-stage company, Definium does not yet generate product revenue and funds its operations through capital markets and cash reserves. Its pipeline is anchored by its lead product candidate, DT120 ODT (lysergide tartrate), an orally disintegrating tablet formulation of a classic serotonergic psychedelic. DT120 ODT is currently advancing through Phase 3 clinical trials for the treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD), having received FDA Breakthrough Therapy Designation for GAD. The company is also developing early-stage candidates, including DT402, an R-enantiomer of MDMA, which is in Phase 2a trials for autism spectrum disorder (ASD). Definium aims to provide treatments that offer long-term remission for mental health conditions rather than transient symptom reduction, positioning itself at the forefront of the emerging psychedelic medicine industry.
